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ABSTRACT 
Background 
The appropriate role of aspmn m heart failure is controversial. 
Retrospective analyses have suggested the use of aspirin may attenuate the benefit 
seen with angiotensin converting enzyme inhibitor (ACEI) therapy. This study 
investigates the relationship between aspirin use and survival in the UNC Heart 
Failure Database. This cohort has substantially greater representation of women 
(32%), African-Americans (44%), and patients with heart failure of a non-
ischemic etiology ( 68%) than previously examined populations. 
Methods 
Data from 872 patients with symptomatic heart failure (HF) and systolic 
dysfunction were reviewed. These patients were enrolled in the UNC Heart 
Failure Database from 1984 through 1999, and were followed for a mean of 3.7 
years. Data on vital status, available in 96% of patients, revealed 392 deaths. The 
Cox proportional-hazards regression method was used to determine the 
relationship of baseline characteristics to all-cause mortality. 
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Results 
Multivariate, adjusted survival analysis indicated aspirin use at baseline 
was associated with a significant reduction in all-cause mortality, with a hazard 
ratio (HR) for aspirin use of0.71 (95% CI 0.55-0.92). In patients taking ACEI at 
baseline, the HR for aspirin use was 0.76 (0.57-1.01) compared to a HR of 0.61 
(0.31-1.19) for those not taking ACEI. In patients with ischemic heart disease 
(lliD) as their primary HF etiology, the HR for aspirin use was 0.65 (0.46-0.94) 
compared to a HR of0.93 (0.64-1.34) for those with a primary HF etiology other 
than lliD. 
Conclusion 
Aspirin use at baseline in patients with symptomatic heart failure was 
independently associated with reduced all-cause mortality. 
4 
INTRODUCTION 
Context 
As the U.S. population ages, and as Americans survlVe longer with 
hypertension and ischemic heart disease (lliD), heart failure (HF) continues to 
increase in prevalence.[!] Currently, this clinical syndrome affects almost five 
million Americans, and based on data from the American Heart Association, over 
500,000 new cases of.HF are diagnosed each year.[2] Despite a steady stream of 
therapeutic advances, heart failure continues to be associated with significant 
morbidity and mortality.[2, 3] 
Over the past two decades, ischemic heart disease has emerged as a major 
etiology of chronic heart failure due to left ventricular (LV) systolic dysfunction 
and studies have demonstrated an increased risk of death when lliD is the primary 
HF etiology. [ 4-6] This increased risk appears to stem from instability in 
atherosclerotic plaques, with platelet-mediated progression leading to chronic 
myocardial dysfunction, even in the absence of clinically overt ischemic 
events. [7, 8] The platelet is now well established to play a critical role in the 
transition from plaque instability to ischemic events in patients with lliD.[7, 8] 
A meta-analysis by the Antithrombotic Trialists' Collaboration associated 
antiplatelet therapy with a significant reduction in cardiovascular events in 
patients with lliD.[9, 10] This implies that antiplatelet agents should be combined 
with standard heart failure therapy in HF patients with lliD. Aspirin would seem 
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to be ideal for this purpose, being both inexpensive and widely studied. However, 
there has been no randomized trial of aspirin in heart failure. 
Angiotensin converting enzyme inhibitors (ACEI) have a well-established 
beneficial effect on morbidity and mortality in patients with left ventricular 
dysfunction and are a fundamental part of standard heart failure therapy. The 
mechanism of this beneficial effect has not been fully elucidated, but is most 
likely derived via alterations in the levels of circulating mediators such as 
bradykinin and certain prostaglandin subtypes. Therefore, the combined use of 
aspirin and ACEI seems logical in patients with HF due to lliD. 
However, retrospective studies have suggested a possible attenuation of 
benefit when using aspirin and angiotensin converting enzyme inhibitors 
together.[ll-14] Aspirin works by inhibiting the cyclooxygenase enzyme (COX-
I), which decreases the conversion of arachadonic acid precursors into vasoactive 
prostaglandins PGI2 and PGE3, as well as the thromboxane, TXAz. This suggests 
a biologically plausible mechanism for an adverse interaction between aspirin and 
ACEI. Since ACEI are a well-established part of heart failure therapy,[15-20] it is 
important to further assess the effects of aspirin in this population. 
In previously reported retrospective studies of aspirin in heart failure, 
patients tended to be white, to be male, and to have ischemic heart disease. To 
provide a different perspective, this study investigated the relationship between 
aspirin use and all-cause mortality in the University of North Carolina heart 
failure database. Data on 872 patients followed from 1984 through 1999 are 
presented here. This cohort has substantially greater representation of women 
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(32%), African-Americans (44%), and patients with heart failure of a non-
ischemic etiology ( 68%) than previously examined populations. 
Aspirin in ischemic heart disease 
The Antiplatelet Trialists' Collaboration has presented a meta-analysis that 
indicates aspirin therapy results in approximately a 25% reduction in vascular 
events, defined as myocardial infarction (MI), stroke (CV A), or cardiovascular 
(CV) death, in several categories of patients at high risk for such events. In 
patients post acute MI, aspirin reduced the subsequent vascular event rate to 10%, 
compared to 14% for placebo. Similarly, in patients with a history ofMI, vascular 
events were reduced to 13% with aspirin, compared to 17% with placebo. The 
relative risk reduction seen in patients with a history of stroke or with several 
other cardiac risk factors was similar. All cause mortality was significantly 
reduced in high-risk patients with a rate of 8.0% for patients taking aspirin 
compared to 9.5% for placebo. The average duration of therapy was 2 years. 
Aspirin doses ranged from 75 to 1500 mg per day, with no material difference in 
efficacy seen based on dose. [21] 
Clear evidence of the benefit of aspirin in acute myocardial infarction was 
demonstrated in the Second International Study of Infarct Survival (ISIS-2). In 
this trial involving 17,187 patients with suspected MI randomized to aspirin, 
streptokinase, both, or neither, a one-month course of aspirin at a daily dose of 
160 mg resulted in a decrease in 5-week vascular mortality from 11.8% in the 
placebo tablets group to 9.4% among patients taking aspirin. This is a 23% (95% 
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CI 15% to 30%) reduction in the odds of death. [22] The Collaborative group of 
the Primary Prevention Project (PPP) reported the results of a randomized 
controlled open-label trial of low-dose aspirin, 100 mg per day, for primary 
prevention of cardiovascular events in patients with one or more risk factors. In 
this trial of 4,495 patients followed for a mean duration of 3.6 years, aspirin 
reduced cardiovascular death from 1.4% to 0.8%, a relative risk of 0.56 (95% CI 
0.31-0.99) [23] 
Angiotensin converting enzyme inhibitors in heart failure 
Several large trials have been published which serve to illustrate the 
benefit of ACEI therapy in HF. The second Veteran's Administration Cooperative 
Vasodilator-Heart Failure Trial (V-HeFT II) showed that the ACEI enalapril 
reduced mortality in patients with symptomatic heart failure. In fact, the reduction 
in mortality seen with enalapril was significantly greater than that seen with the 
combination of hydralazine and isosorbide dinitrate, suggesting that the beneficial 
effect of ACEI is more than can be explained by its properties as a vasodilator. 
The cumulative mortality at one year was 9% for enalapril, compared to 13% for 
hydralazine-isosorbide dinitrate and an estimated 20% for placebo. This dramatic 
relative advantage decreased, but still persisted, over four years where the 
cumulative mortality for enalapril was 42% compared to 47% for hydralazine-
isosorbide dinitrate and an estimated 54% for placebo.[l5] 
The two concurrent Studies of Left Ventricular Dysfunction (SOL VD) 
randomized clinical trials used a patient population with EF:S35% both with 
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(Treatment trial) and without (Prevention trial) clinical HF. The SOL VD 
Treatment trial randomized 2,569 patients to enalapril vs. placebo and used the 
primary endpoint of all-cause mortality. Patients randomized to enalapril had a 
lower rate of death (35.2% vs. 39.7% for placebo, p<0.0036) with a risk reduction 
of 16% (95% CI 5% to 26%).[16] 
The SOL VD Prevention trial was also designed to examine the primary 
endpoint of all-cause mortality as well as secondary endpoints of unstable angina 
(USA), MI, CV death, and development of HF. The 4,228 patients were also 
randomized to enalapril vs. placebo and followed for an average of 40 months. 
There was a non-significant trend toward lower all-cause mortality with enalapril 
(14.8% vs. 15.8% for placebo, p=0.30) and there was a statistically significant 
difference in development of HF that favored enalapril (20. 7% vs. 30.2% for 
placebo) with a risk reduction of37% (95% CI 28% to 44%).[17] 
For the composite endpoint of CV death or non-fatal MI, enalapril had 
lower mortality in patients with HF (33.4% vs. 39.3% for placebo) for a risk 
reduction of 19% (95% CI 8 to 29%). In patients without clinical HF, the risk 
reduction with enalapril was similar (15.6% vs. 19.5% for placebo), with a value 
of 23% (95% CI 11% to 33%). The relative risk reduction for enalapril vs. 
placebo was roughly the same for each of the three previously mentioned 
mortality.[18] 
In the Survival and Ventricular Enlargement (SAVE) study, 2,231 patients 
who were post-MI with decreased left ventricular ejection fraction (L VEF) but 
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without clinical HF were randomized to captopril vs. placebo and followed for an 
average of 42 months. All-cause mortality was significantly reduced by captopril 
(20% vs. 25%, p=0.019) This was a 19% risk reduction (95% CI 3% to 32%) 
which was present out to an average of 42 months, however no difference in 
mortality was apparent until after one year. Roughly similar reductions were seen 
in non-fatal major cardiovascular events, such as development of heart failure and 
recurrent MI. The subgroup taking aspirin had a significantly lower mortality rate 
with ramipril (16.6% vs. 21.4% for placebo) with a relative risk reduction of24% 
(95% CI 2% to 41%). In contrast, the subgroup not taking aspirin had no 
significant difference in mortality with ramipril (26.0% vs. 29.2% for 
placebo). [ 19] 
The Acute Infarction Ramipril Efficacy (AIRE) study was a randomized, 
double blind trial that investigated the effect of ramipril, an oral ACEI, in 2, 006 
hemodynamically stable post-MI patients with mild to moderate clinical heart 
failure. Patients assigned to ramipril had significantly lower all-cause mortality at 
an average of 15 months compared to placebo (17% vs. 23%, p=0.002) for a 
relative risk reduction of 27% (95% CI 11% to 40%). The point estimate for the 
relative risk of death (ramipril vs. placebo) for the subgroup taking aspirin was 
approximately 0.8 compared to approximately 0.6 for the subgroup not taking 
. . b h. d"ffi . . 11 • "fi asptnn, ut t 11s 1 erence was not stattstlca 1y stgm. 1cant, and there was no 
statistically significant interaction between the two.[20] 
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Angiotensin converting enzyme inhibitors in ischemic heart disease 
ACEI have also been shown to have a beneficial cardiovascular effect in high-risk 
patients with normal L VEF, as well as in acute coronary syndromes. The 
Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) 
randomized post-MI patients to ACEI (IV enalaprilat followed by oral enalapril) 
or placebo. The study was stopped after enrolling 6,090 of a planned 9,000 
patients due to interim evaluations suggesting a low likelihood that a statistically 
significant result would be achieved and a concern over potential adverse effects 
of enalapril treatment. At the time the trial was stopped there was no statistically 
significant difference in all-cause mortality between enalapril and placebo, 
although slightly more patients had died at six months on the ACEI (1 0.2% vs. 
9.4% for placebo, p=0.026).[24] More recently, the Heart Outcomes Prevention 
Evaluation (HOPE) study randomized 9,297 high-risk patients without known LV 
dysfunction or symptoms of heart failure to the ACEI rarnipril vs. placebo, with 
the composite endpoint being MI, CV A, or CV death. The study showed that 
rarnipril significantly reduced the risk of the composite endpoint (14.0% vs. 
17.8% for placebo, relative risk 0.78, 95% CI 0.70 to 0.86).[25] 
11 
Aspirin and Angiotensin converting enzyme inhibitors interaction 
Administration of ACEI results in the accumulation of bradykinin, which 
may have beneficial effects by promoting vasodilation and limiting cardiac 
remodeling. Experimental evidence suggests the influence of bradykinin accounts 
for at least part of the benefit of ACEI in HF or post-MI.[l2, 26] Beneficial 
effects of bradykinin appear to be related to activation of NO production and 
COX which stimulate synthesis of a variety of PG's which have vasoactive and 
cytoactive effects that may be beneficial in these diseases.[19] In contrast, aspirin 
blocks COX, which in tum decreases the conversion of the precursors of 
arachadonic acid to vasoactive prostaglandins like PGiz and PGE3. [27] 
The issue of possible attenuation of the effect of ACEI by aspirin has been 
an area of intense debate. Given potential deleterious effects of aspirin with 
respect to renal function[28, 29] or dyspepsia/gastrointestinal bleeding,[30] its use 
in HF patients is not without potential harm. Prostaglandins (PG) play an 
important endogenous vasodilatory role and counteract the enhanced peripheral 
vasoconstriction state of heart failure.[13] ACEI reduce plasma levels of the 
vasoconstrictor angiotensin II (ATII); they also inhibit breakdown of bradykinin 
(BK) that stimulates PG synthesis. Increase in BK is the predominant reason for 
the antihypertensive effect of ACEI.[ll] The beneficial effect of ACEI cannot be 
entirely explained by the inhibition of ATII. ACEI produce persistent benefits, 
although circulating levels of ATII gradually return to normal. [ 13] A study found 
that patients with severe HF had levels of PGE2 and PGiz that were three to ten 
times higher than healthy subjects. Indomethacin, a non-steroidal anti-
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inflammatory drug that inhibits PG synthesis, caused worsenmg 
hemodynamics. [II] 
Using invasive hemodynamic monitoring, Hall and co-workers observed 
that aspirin inhibited the vasodilator effect of enalapril in patients with severe 
HF. [31] Guazzi and colleagues showed that enalapril improved pulmonary gas 
exchange and lung volumes. Beneficial changes in pulmonary gas exchange were 
counteracted by aspirin.[26] A dose of 325 mg aspirin was given for 8 weeks to 
patients with dilated cardiomyopathy and NYHA class II-III HF (18 on ACEI, 8 
not on ACEI, not randomized). Aspirin had inhibitory effect on measures of 
oxygen exchange. [32] In a 1993 study, van Wijngaarden, et al. determined that 
the ACEI captopril, given alone, did not change circulating levels of the 
vasodilatory prostaglandins PGI2 and PGE2 or the vasoconstricting thromboxane 
A2 (TXA2). However, co-administration of a single dose of aspirin reduced 
circulating PGE2 and TXA2 levels, without a corresponding hemodynamic 
effect. [27] In this study, a low dose of aspirin was used. Low doses of aspirin 
inhibit TXA2; higher doses are needed to reduce PG's.[27] Evans, et al., found no 
hemodynamic, neurohumoral, or renal effect of low dose aspirin alone in a canine 
model. [33] 
In addition to in vitro studies, retrospective data analysis has been done on 
data from several cliPical trials. A retrospective ana!ysis[34] of patients in the 
combined SOL VD trials[ 16, 17] examined the possibility that there might be a 
clinically significant interaction between the effect of antiplatelet agents and that 
of the ACEI enalapril. Although specific details of antiplatelet therapy were not 
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collected, clopidogrel was not available, and the use of dipyridamole was limited, 
so the anti-platelet agents referred to in SOL VD can safely be assumed to be 
aspirin. In patients taking aspirin there was no benefit to enalapril, while in 
patients not taking aspirin, there was benefit if randomized to enalapril. Adjusted 
for confounders, anti platelet agent (AP A) use was associated with reduction in 
CV death, but not associated with death due to worsening HF or non-cardiac 
death. Point estimates for the effects of AP A in the combined group were: all 
cause mortality (0.82), CV death (0.80), sudden death (0.78), HF death (0.92/NS), 
fatal MI (0.58), and non-CV death (1.27/NS). 
No significant interaction between aspirin use and enalapril was seen with 
respect to mortality; however a significant association between aspirin use and 
survival was seen only in patients with an ischemic etiology. There was a non-
significant trend toward improved survival among non-ischemics receiving 
aspirin. The HR for enalapril users vs. non-users for all cause mortality stratified 
by aspirin use were: aspirin (1.1 0/NS), no aspirin (0. 77). Possible explanations for 
these results are: 1) aspirin antagonizes enalapril, 2) aspirin and enalapril derive 
benefit via same mechanism, or 3) the interaction between aspirin and enalapril is 
multifactorial. 
Results from two analyses of post-MI trials have also suggested cause for 
concern. In a retrospective analysis[34] of data from the CONSENSUS II 
study,[24] the authors found that the enalapril-aspirin interaction was 
antagonistic. Furthermore, they determined that this interaction was a significant 
predictor of mortality at the end of the study (p=0.047). A combined retrospective 
14 
analysis of patients from the GUSTO-I and EPILOG trials[12] determined that the 
combined use of aspirin and ACEI was associated with increased mortality in 
GUSTO-I patients (HR 2.2, 95% CI 1.1 to 4.3) and in EPILOG patients (HR 2.1, 
95% CI 1.1 to 3.8) compared with aspirin alone. 
A post hoc analysis of the Captopril and Thrombolysis (CATS) study[35] 
showed that aspirin did not attenuate effects of ACEI after acute MI, but 
independently reduces LV dilation after MI. The Acute Myocardial Infarction 
Survival (AMIS) trial[28] showed an increase in mortality in most subgroups with 
aspirin, while the second Persantine Aspirin Reinfarction Study (PARIS 11)[29] 
showed an overall trend toward benefit, but a trend toward harm in heart failure. 
These are older studies and used higher aspirin doses, up to 1500 mg/day.[14] 
The Acute Infarction Ramipril Efficacy (AIRE) study also suggested an 
interaction between ACEI use and the effect of aspirin on mortality in HF 
patients. The point estimates for the relative risk of death for the subgroup taking 
aspirin suggested less benefit from ACEI compared to the subgroup not taking 
aspirin, although investigators were unable to show a statistically significant 
interaction between the two drugs.[20] In the Survival and Ventricular 
Enlargement (SAVE) trial also, no interaction between aspirin use and the effect 
of ACEI on mortality was seen.[19] Finally, in the Benzafibrate Infarction 
0·e·ve-tt·~- 'BTD\ • ..:"1 Af"'PT :- "~mb:nat:on ""•h aspt"n"n ha-l a b~n~r.l":at ~""~~• 
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on mortality compared with aspirin alone, both overall and in the subgroup of 
patients with CHF.[11] 
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Limitations related to the available clinical data concerning the aspmn-
ACEI interaction must be acknowledged. Analysis of the SOL VD and 
CONSENSUS II data was done on a retrospective basis. Patients were not 
randomly assigned to aspirin use in these studies. Unknown differences in 
baseline characteristics, not accounted for in the statistical analysis, might have 
existed. In contrast, studies using hemodynamic end points, like SVR, were done 
prospectively and clearly indicate that antagonism of the hemodynamic effects of 
ACEI by aspirin occurs. The effect may be dose-dependent. One alternative 
explanation for the lack of additive benefit from ACEI and aspirin is that the 
principal effects of ACEI were anti-ischemic. [ 11] Aspirin may negate the benefits 
of ACEI, or it may be that ACE offers no additional advantage.[14] 
In summary, previous work on aspirin in heart failure has been somewhat 
contradictory, but has suggested that there may be an adverse interaction between 
aspirin and ACEI such that use of aspirin in HF patients taking ACEI may need to 
be reconsidered. The greatest weakness of the prior published data is the absence 
of any randomized controlled trial of aspirin in heart failure. Given that such an 
undertaking is at this time unlikely, the best current evidence comes from a 
synthesis of retrospective data sources. The principal data sources being 
considered, as described above, have generally used a patient population that is 
in these older studies is generally white and male. The present study provides a 
new perspective by examining a population where African-Americans, women, 
and patients with HF of a non-ischemic etiology are more strongly represented. 
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METHODS 
Patients 
The present study utilizes data from the University of North Carolina 
Heart Failure Database. All patients seen in the University of North Carolina 
heart failure clinic are entered into the database at the time of their initial clinic 
visit. History and physical examination findings at that time are recorded, 
including a detailed medication history. For the purposes of this study, 
medications initiated at a patient's first visit are considered part of their baseline 
medications. The majority of patients received their continuing care in the 
University of North Carolina heart failure clinic according to the general heart 
failure guidelines at the time of the patient's enrollment. However, treatment was 
not rigorously standardized, as it would have been in a clinical trial. 
This study population consists of the 872 patients that were enrolled from 
the inception of the database in 1984 until 1999. All patients had a clinical 
diagnosis of heart failure based on at least one of the following criteria: dyspnea 
at rest, exertional dyspnea, or fluid retention believed to be of cardiac origin. The 
University of North Carolina Chapel Hill Committee on the Protection of the 
Rights of Human Subjects (School of Medicine Institutional Review Board) 
approved this research protocol, and informed consent to participate was obtained 
from all study participants. 
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Variables 
Information on New York Heart Association class, aspmn and ACE 
inhibitor use at baseline, gender, age, and history of diabetes was obtained from a 
detailed history and physical examination at time of study entry. Available 
clinical, laboratory and autopsy data were used to assign a primary etiology for 
heart failure and to determine the presence or absence of coronary artery disease 
in each patient. Presence of atrial fibrillation was determined by baseline 
electrocardiogram. Left ventricular ejection fraction and left ventricular volume 
were determined by radionuclide ventriculography within 6 months of study 
entry. Vital status was ascertained at last follow-up from contact with the patient, 
a family member, or the referring physician, and was used to assign a cause of 
death. Patients undergoing cardiac transplantation were considered alive and 
censored at the time of surgery. 
Analysis 
Statistical analysis was performed usmg the SAS software package 
(Version 8.2, SAS Institute, Cary NC). Bivariate analysis was performed for all 
independent variables against the primary outcome of all cause mortality, and 
against the principal exposure of aspirin use. P-values are reported from 
individual comparisons using Student's t-test or the Chi-square test as appropriate, 
with two-sided p-values of less than 0.05 considered statistically significant. 
Cumulative survival curves were constructed by Kaplan-Meier methods with 
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differences between the curves tested for significance by the log-rank 
statistic. [3 6] 
The Cox proportional-hazards regression method was used to determine 
the relationship of baseline characteristics to outcome. [37] Models were also 
used to evaluate for a possible effect modification on the relationship between 
aspirin use and survival due to ACE inhibitor use or to lliD etiology. The 
following clinical variables, based on clinical significance and on the baseline 
evaluation, were considered as potential confounders: ACE inhibitor use at 
baseline, New York Heart Association class, ischemic versus non-ischemic 
primary etiology of heart failure, gender, age, left ventricular ejection fraction, 
left ventricular end diastolic volume index, presence of atrial fibrillation, and 
history of diabetes. 
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RESULTS 
Baseline characteristics 
Table 1. Baseline characteristics of UNC HF Cohort As shown in 
(n=872) 
Table 1, mean age was 
N mean±SD 
Age (years) 872 51.1 ± 13.7 
Length offollow-up (years) 872 3.7 ± 3.0 51±14 years, mean 
LVEF (%) 872 26.3 ± 13.5 
NYHA Functional Class 872 2.82 ± 0.72 LVEF was 
N % 26.3±13.5%, and mean 
Male 597 68.5% 
White 480 56.3% NYHA functional 
HTN 480 55.0% 
DM 217 24.9% 
PriorCABG 128 15.4% class was 2.83±0.72. 
IHD Primary Etiology of HF 278 31.9% 
Atrial Fibrillation 83 9.6% This cohort was 56.3% 
Medication 
Aspirin 227 26.0% white, with the 
Digoxin 653 74.9% 
Loop Diuretic 703 80.6% 
ACE Inhibitor 699 80.2% 
remainder being 
Beta blocker 44 5.1% 
Hydralazine 54 6.2% African-American. 
Spironolactone 23 2.6% 
UNC- University of North Carolina, HF= heart failure, LVEF= Hypertension and 
left ventricular ejection fraction, NYHA= New York Heart 
Association, HTN= hypertension, DM= diabetes mellitus, diabetes were common 
CABG= coronary artery bypass graft, IHD= ischemic 
heart disease, ACE= angiotensin converting enzyme comorbidities. The 
primary HF etiology was lliD for 31.9% of this population, and daily aspirin use 
overall in this population was 26.0%. This compares to utilization rates of 74.9% 
for digoxin, 80.6% for loop diuretics, and 80.2% for ACE inhibitors. Only 5.1% 
of this population was taking a beta-blocker, and 2.6% were taking spironolactone 
at baseline, reflecting standard practice over the time these data were being 
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collected. Other commonly used drugs in our population included long-acting 
nitrates (20.2%), calcium channel blockers (13.8%), and warfarin (36.7%). 
Table 2. Baseline characteristics of aspirin users and non-users in the UNC HF Cohort 
{n=854) 
ASA Users {n=219) 
I I 
Non-users {n=635) 
I I 
N mean± SO N mean+ SO p-value 
Age {years) 219 55.0±11.6 635 49.9 ± 14.1 <0.0001 
Length of follow-up {years) 219 6.9 ± 2.5 635 8.9 ± 3.5 <0.0001 
N % N % p-value 
Male 164 75.0% 421 66.0% 0.0183 
White 145 66.2% 335 52.8% 0.0006 
HTN 137 63.0% 334 53.0% 0.0106 
OM 76 35.0% 137 22.0% 0.0001 
prior CABG 67 33.0% 58 9.5% <0.0001 
IHO Primary Etiology of HF 119 54.0% 152 24.0% <0.0001 
Atrial Fibrillation 12 5.6% 70 11.0% 0.0178 
Medication 
ACE Inhibitor 87.0% 78.0% 0.0029 
Warfarin 23.0% 42.0% <0.0001 
UNC University of North Carolina, HF heart failure, ASA aspirin, HTN hypertension, DM 
diabetes mellitus, CABG= coronary artery bypass graft, IHD= ischemic heart disease, 
ACE= angiotensin converting enzyme 
Characteristics of aspirin users vs. non-users overall 
As shown in Table 2, patients taking aspirin were older than patients not 
taking aspirin, while patients not taking aspirin had longer mean follow-up 
duration. Patients taking aspirin were more likely to be male (75% vs. 66%, 
p=O.Ol83), to be white (66% vs. 53%, p=0.0006), to be hypertensive (63% vs. 
53%, p=O.Ol06), to be diabetic (35% vs. 22%, p=O.OOOl), and to have had prior 
bypass surgery (33% vs. 9.5%, p<O.OOOl). As expected, patients taking aspirin 
were also more likely to have an ischemic primary etiology for their heart failure 
(54% vs. 24%, p<O.OOOl) and to be taking ACEI (87% vs. 78%, p=0.0029). The 
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patients not taking aspirin had a higher prevalence of atrial fibrillation (11% vs. 
5.6%, p=0.0178) and were more likely to be on anticoagulants (42% vs. 23%, 
p<0.0001). In Table 3, a description of patient characteristics for the 699 patients 
on ACE inhibitor is shown. The differences in descriptive statistics for aspirin 
use or non-use in patients taking ACEI at baseline were essentially the same as 
those for aspirin use versus non-use in the overall population. 
users vs non-users among users 
ASA Users (n=197) Non-users (n=502) 
I 
54 
enzyme 
ASA= aspirin, LVEDVI= left ventricular end diastolic volume index, LVESVI= left ventricular end 
systolic volume index, HTN= hypertension, DM=diabetes mellitus, CABG= coronary artery bypass 
IHD= ischemic heart disease 
Characteristics of aspirin users vs. non-users by etiology 
As shown in Table 4, for the 278 patients with lliD as their primary heart 
failure etiology, there was little significant difference between groups based on 
aspirin use or non-use. Patients not taking aspirin were more likely to have atrial 
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fibrillation (15.1% vs. 3.3%, p=0.0010) and trended toward a higher likelihood of 
taking warfarin than those taking aspirin (45.5% vs. 29.0%, p=0.0051), although 
absolute numbers were small. Table 5 summarizes patient characteristics for the 
subset of patients without ischemic heart disease. For the 594 patients with a 
primary heart failure etiology other than IHD, the differences in descriptive 
statistics based on aspirin use or non-use were similar to those for aspirin use or 
non-use in the overall population with a few exceptions. Patients without IHD as 
a primary HF etiology taking or not taking aspirin were equally likely to be male 
or to be white. Overall likelihood of atrial fibrillation was similar between the 
two groups, but patients not taking aspirin had a higher likelihood of taking 
warfarin than those taking aspirin (40.3% vs. 15.5%, p<0.0001). 
Table 4. Baseline characteristics of aspirin users vs non-users among patients with 
an IHD HF etioloQV in the UNC HF Cohort ln=278) 
ASA Users (n=124) 
I I 
Non-users (n=154) 
I I 
N mean +SO N mean ±SD p-value 
Aqe lvearsl 124 57.1 ± 10.0 154 58.5± 11.0 0.2938 
Body mass lk!1/m2l 118 25.8 + 4.4 146 26.0 ± 4.8 0.7218 
LVEF (units) 124 25.0 ± 10.9 154 24.1 ± 10.3 0.5213 
LVEDVI (ml/m2) 120 169.2 ± 58.5 147 176.9 + 61.3 0.2868 
NYHA Functional Class 124 2.86 ± 0.70 154 2.93 ± 0.76 0.4593 
N % N % p-value 
Male 108 87.1% 133 86.4% 0.8580 
White 101 84.9% 117 77.0% 0.1037 
HTN 66 53.2% 82 53.3% 0.9972 
DM 42 33.9% 53 34.4% 0.9242 
prior CABG 67 55.4% 57 38.3% 0.0050 
Atrial Fibrillation 4 3.3% 23 15.1% 0.0010 
Medication 
ACE Inhibitor 103 83.1% 117 76.0% 0.1481 
Warfarin 36 29.0% 70 45.5% 0.0051 
ACE angiotensin converting enzyme, UNC- University of North Carolina, HF- heart failure, 
ASA= aspirin, LVEDVI= left ventricular end diastolic volume index, IHD= ischemic heart disease 
HTN= hypertension, DM=diabetes mellitus, CABG= coronary artery bypass graft 
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Table 5. Baseline characteristics of aspirin users vs non-users among patients with 
a non-IHO HF etiology in the UNC HF Cohort Jn=594) 
ASA Users (n=103) 
I I 
Non-users (n=491) 
I I 
N mean+ SO N mean± SO p-value 
Age (years) 103 52.8 ± 12.7 491 46.9 + 13.9 <0.0001 
Body mass (kg/m2) 98 29.0 + 7.5 477 27.6 ± 6.8 0.0638 
LVEF (%) 103 29.3 + 14.5 491 26.8 + 14.6 0.1054 
LVEOVI (mllm2) 101 171.5 ± 75.7 471 187.9 ± 69.2 0.0344 
NYHA Functional Class 103 2.80 ± 0.65 491 2.78 ± 0.72 0.8131 
N % N % p-value 
Male 63 61.1% 293 59.7% 0.7789 
White 44 44.0% 218 45.2% 0.8222 
HTN 77 74.8% 255 51.9% <0.0001 
OM 37 35.9% 85 17.4% <0.0001 
priorCABG 2 2.2% 2 0.4% 0.0633 
Atrial Fibrillation 8 7.9% 48 9.8% 0.5580 
Medication 
ACE Inhibitor 94 91.3% 385 78.4% 0.0027 
Warfarin 16 15.5% 198 40.3% <0.0001 
ACE- angiotensin converting enzyme, UNC- University of North Carolina, HF= heart failure, 
ASA= aspirin, LVEDVI= left ventricular end diastolic volume index, IHD= ischemic heart disease 
HTN= hypertension, DM=diabetes mellitus, CABG= coronary artery bypass graft 
Survival Analysis 
Unadjusted Kaplan-Meier curves for aspirin users and non-users overall 
showed no apparent difference in all-cause mortality, as shown in Figure 1. This 
lack of apparent difference was also seen in the unadjusted curves with the 
population limited to those patients using ACEI at baseline, as shown in Figure 2. 
Once adjusted for confounding, however, separation between the curves is 
apparent. The resulting curves from adjusted multivariate Cox proportional-
hazards analysis are shown in Figure 3. 
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Figure 1. Survival (Kaplan-Meier) curves for aspirin users (dashed line) and non-
users (solid line). Results are unadjusted, and outcome is all-cause mortality. 
Vertical axis is percent survival, and horizontal axis is length of follow-up in 
days. 
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Figure 2. Survival (Kaplan-Meier) curves for aspirin users (dashed line) and non-
users (solid line), among patients taking ACEI at baseline. Results are unadjusted, 
and outcome is all-cause mortality. Vertical axis is percent survival, and 
horizontal axis is length of follow-up in days. 
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Figure 3. Survival (Cox proportional-hazards analysis) curves for aspirin users 
(dashed line) and non-users (solid line), among patients taking ACEI at baseline. 
Results are adjusted for New York Heart Association Class, left ventricular 
ejection fraction, sex, age, left ventricular end diastolic volume, atrial fibrillation, 
and diabetes mellitus. Outcome is all-cause mortality. Vertical axis is percent 
survival, and horizontal axis is length offollow-up in days. Top-most dashed line 
is the curve for patients on ACEI and aspirin, solid line represents patients on 
ACEI but not aspirin, and the lowest dashed line (poorest survival) represents 
patients on neither ACEI nor aspirin. 
Overall, the hazard ratio for mortality based on aspirin use was 0.711 
(95% CI 0.550-0.920), indicating patients taking aspirin at baseline had a 29% 
lower mortality compared with those not taking aspirin. Stratifying into groups 
based on ACEI use at baseline, the patients taking ACEI and aspirin at baseline 
had a 24% lower mortality of borderline statistical significance (HR 0. 758, 95% 
CI 0.572-1.005), while those not taking ACEI showed a trend toward a 39% lower 
mortality with aspirin use (HR 0. 608, 95% CI 0. 311-1.187), but due to the 
relatively small number of patients in this category, the confidence interval is 
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wide. There was no statistically significant effect modification due to ACE use 
on the relationship between aspirin use and mortality. 
Stratified into groups based on HF etiology, the patients with known lliD 
as a primary etiology of their heart failure had a 3 5% lower mortality with aspirin 
use (HR 0.654, 95% CI 0.455-0.939). Patients without known lliD showed no 
statistically significant benefit from aspirin use (HR 0.926, 95% CI 0.639-1.341). 
Once again, there was no statistically significant effect modification due to 
etiology on the relationship between aspirin use and mortality. The results of 
adjusted multivariate Cox proportional-hazards analysis are shown in Table 6. 
Table 6. Relative hazard of all-cause mortality for patients using 
aspirin (ASA) at baseline compared to aspirin non-users, 
combined, stratified by ACEI use, and stratified by IHD etiology 
N HR for ASA use• 95%CI 
All Patients 832 0.711 0.550-0.920 
Stratified on ACE-I use 
Taking ACE-I 674 0.758 0.572-1.005 
Not taking ACE-I 158 0.608 0.311-1.187 
Stratified on IHD etiology 
IHD etiology 264 0.635 0.442-0.911 
Non-IHD etiology 568 0.708 0.612-1.397 
HR= hazard ratio, determined by Cox Proportional Hazards analysis, HR 
and 95% confidence interval (CI) are adjusted for New York Heart 
Association functional class, left ventricular ejection fraction, sex, age, 
left ventricular end diastolic volume, atrial fibrillation, diabetes mellitus, 
angiotensin converting enzyme inhibitor (ACEI) use, and ischemic heart 
disease (IHD) as a primary her! failure etiology 
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DISCUSSION 
In this study population, aspirin use is associated with a statistically 
significant 29% reduction in all-cause mortality using a multivariate Cox 
proportional hazards analysis. Although there was no detectable statistically 
significant interaction between aspirin use and ACEI use or lliD etiology with 
respect to all-cause mortality, the results of the stratified analyses are suggestive. 
First, there was a trend toward benefit from aspirin in those patients taking ACE 
inhibitors, and a trend toward larger benefit in patients not taking ACEI. The 
point estimates suggested a 24% reduction in the ACEI group and a 39% 
reduction in the non-ACEI group (full details in Table 6). Although these results 
must be interpreted with caution, the trend is still consistent with the hypothesis 
that ACEI use may lessen the benefit of aspirin use. 
Second, there was a statistically significant 3 7% all-cause mortality 
benefit with aspirin use in patients with an lliD etiology, and a trend toward 
benefit from aspirin in patients with HF etiologies other than lliD. The point 
estimate for the non-lliD group suggested a 29% reduction in all-cause mortality. 
Again, these results must be interpreted with a great deal of caution due to the 
relatively wide confidence intervals. 
On balance, previously available evidence appears to support a beneficial 
effect overall from using aspirin in heart failure, and this is consistent with the 
results observed in this study population. However, given the ubiquitous nature of 
ACEI use in this population, an equally important question is whether addition of 
aspirin provides additional benefit to these patients. Here, the previous evidence is 
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m conflict, with some studies suggesting a benefit, while others suggest no 
benefit, or even harm. Examination of this patient population lends support to the 
proposition that addition of aspirin provides additional benefit over ACEI alone, 
although this additional benefit was unable to be demonstrated with statistical 
significance at the p<0.05 level due to insufficient power. 
The observed trend toward benefit with aspirin use m patients taking 
ACEI appears smaller than that observed in the patients not taking ACEI, 
consistent with the hypothesis that there is some negative interaction between 
ACEI use and the mortality benefit of aspirin. However, numbers in this category 
are relatively small, and the confidence interval is wide, so these results must be 
interpreted with caution. There was no statistically significant interaction term for 
the effect of ACEI use on the relationship between aspirin and mortality, but it is 
reasonable to believe that such an interaction may exist and that this study lacked 
sufficient power to demonstrate this effect. 
Finally, the SOL VD subgroup analysis described previously suggests that 
the benefit of aspirin may be limited to patients with an lliD primary heart failure 
etiology. This current analysis of the relationship between etiology and the effect 
of aspirin on survival confirms a statistically significant mortality benefit with 
aspirin use in those patients with an lliD primary heart failure etiology, and 
1 b "11 '- . 1 b fi . h . . " . HF suggests a 1esser, ut st1 suustant1a1, ene1 t 1n t1 ose pattents w1tu a pnmary 
etiology other than lliD. The SOLVD subgroup analysis was unable to 
demonstrate a benefit in the latter group, but this may be due, at least in part, to 
the relatively small number of non-ischemics in the SOL VD cohort. 
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In general, the differences between these results and those based on the 
SOL VD data are interesting, and do not all lend themselves to easy explanation. 
Certainly, this patient population was quite different from the SOL VD cohort. In 
addition to demographic differences, the UNC population was selected based on 
symptomatic HF rather than ejection fraction. In both the UNC and the SOL VD 
cohorts, as in all of the previously mentioned analyses, patients were not 
randomly assigned to aspirin, so unknown differences in baseline characteristics, 
might have existed and not been accounted for in the statistical analysis. In 
addition, patients in the UNC cohort were not randomized to ACEI. UNC patients 
were followed in a specialty heart failure clinic, which was not a common practice 
at the time of the SOL VD trials, and it is possible that we are to some extent 
seeing the effect of a difference in follow-up. 
Additional limitations of the present study include the small sample size 
and non-standardized care. Furthermore, there have been substantial changes in 
the standard of care of HF patients over the time frame covered here, with the 
most obvious of these being the addition of beta-blocker therapy. The effect this 
may have on the observed benefit seen with aspirin use is not clear, but it is 
possible that the protective effect of beta-blockade from an lliD standpoint may 
limit the additional benefit attributable to aspirin. 
This study is retrospective and may suffer from some difficulties from 
measurement of the exposure. Although best efforts were undertaken to obtain an 
accurate medication history, there is a possibility that patients failed to report 
over-the-counter aspirin therapy. This should bias the results toward the null. A 
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more troubling issue is that exposure is classified based on the initial clinic visit, 
and no record is kept of whether patients initiated or discontinued therapy with 
aspirin or ACEI. Finally, there are generalizability concerns stemming from the 
single provider and single site nature of the UNC cohort, and the fact that this is a 
tertiary care setting. However, the increased proportion of patient types not as 
commonly seen in prior trial-based studies (blacks, women, patients with a non-
ischemic HF etiology) does serve to complement the previously published work. 
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CONCLUSION 
Multivariate, adjusted survival analysis indicates aspirin use at baseline 
was independently associated with reduced all-cause mortality in patients with 
symptomatic HF. The overall hazard ratio for aspirin use was 0.711 (95% CI 
0.550-0.920), and the benefit of aspirin was apparently largely preserved in 
patients taking ACEI at baseline, where the HR for aspirin use was 0.758 (0.572-
1.005). In patients with lliD as their primary HF etiology, the HR for aspirin use 
was 0.635 (0.442-0.911) compared to a HR of0.710 for those with a primary HF 
etiology other than lliD, suggesting that both groups can benefit from addition of 
aspirin. 
The ideal follow-up study testing aspirin in heart failure and testing the 
potential aspirin-ACE! interaction would be a large randomized trial of aspirin vs. 
placebo. However, the growing body of secondary data supporting the use of 
aspirin in heart failure complicates the planning of further research. Not only may 
it be difficult ethically to randomize HF patients with lliD not to receive aspirin, 
but also on a practical level, it would likely be very difficult to get physicians to 
agree to enroll patients. 
If a large RCT of aspirin in HF is impractical, two other potential studies 
could be of benefit in this situation. First would be a trial of aspirin vs. 
clopidogrel, an antiplatelet agent acting through a different mechanism and 
unlikely to interact with ACEI. This trial could be performed in HF patients with 
lliD taking ACEI. The major difficulty with implementing this would be cost and 
size, as a large trial would be needed to detect relatively small differences. A 
32 
second potential avenue for further study would be a randomized trial of aspirin 
vs. placebo for primary prevention of CV events and death in patients with HF of 
a non-ischemic etiology. Once again, the major difficulty with implementing this 
would be cost and size. Until such time as this further research is done, current 
best evidence supports the use of aspirin in patients with heart failure who have 
ischemic heart disease, whether or not they are taking angiotensin converting 
enzyme inhibitors. 
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